Back to Archived Journals » Cell Health and Cytoskeleton » Volume 7

The retinoblastoma protein: a master tumor suppressor acts as a link between cell cycle and cell adhesion

Authors Engel B, Cress W D, Santiago-Cardona P

Received 20 September 2014

Accepted for publication 4 November 2014

Published 18 December 2014 Volume 2015:7 Pages 1—10

DOI https://doi.org/10.2147/CHC.S28079

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Denis Wirtz


Brienne E Engel,1 W Douglas Cress,1 Pedro G Santiago-Cardona2

1Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Department of Biochemistry, Ponce School of Medicine, Ponce, Puerto Rico, USA


Abstract: RB1 was the first tumor suppressor gene discovered. Over 4 decades of work have revealed that the Rb protein (Rb) is a master regulator of biological pathways influencing virtually every aspect of intrinsic cell fate including cell growth, cell-cycle checkpoints, differentiation, senescence, self-renewal, replication, genomic stability, and apoptosis. While these many processes may account for a significant portion of RB1's potency as a tumor suppressor, a small but growing stream of evidence suggests that RB1 also significantly influences how a cell interacts with its environment, including cell-to-cell and cell-to-extracellular matrix interactions. This review will highlight Rb’s role in the control of cell adhesion and how alterations in the adhesive properties of tumor cells may drive the deadly process of metastasis.

Keywords: cadherin, integrin, Rb, cancer, aggressiveness, metastasis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]